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A	nonblinded,	positively	controlled,	noninferiority	trial	was	conducted	to	evaluate	the	
efficacy	of	an	alternative,	nonantibiotic	therapy	with	Masti	Veyxym®	to	reduce	ineffec-
tive	antibiotic	usage	in	the	treatment	of	nonsevere	clinical	mastitis	(CM)	in	cows	with	
longer	lasting	udder	diseases.	The	solely	intramammary	treatment	with	Masti	Veyxym® 
(three	applications,	12	hr	apart)	and	the	combined	treatment	with	Masti	Veyxym® and 
antibiotics	as	usual	on	the	farm	according	to	label	of	the	respective	product	were	com-
pared	with	the	reference	treatment	of	solely	antibiotic	therapy.	The	matched	field	study	
was	conducted	on	eight	free-	stall	dairy	farms	located	in	Eastern	Germany.	Cases	of	mild-	
to-	moderate	CM	in	cows	with	longer	lasting	high	somatic	cell	counts	in	preceding	dairy	
herd	improvement	test	days	and	with	previous	CM	cases	in	current	lactation	were	ran-
domly	allocated	to	one	of	the	three	treatment	groups.	A	foremilk	sample	of	the	affected	
quarter	was	taken	before	treatment	and	again	approximately	14	days	and	21	days	after	
the	end	of	therapy	for	cyto-	bacteriological	examination.	Primary	outcomes	were	clinical	
cure	 (CC)	and	no	CM	recurrence	within	60	days	after	the	end	of	treatment	 (no	R60).	
Bacteriological	cure	 (BC)	and	quarter	somatic	cell	count	 (QSCC)	cure	were	chosen	as	
secondary	outcomes	although	low	probabilities	of	BC	and	QSCC	cure	for	selected	cows	
were	expected.	The	study	resulted	in	the	following	findings:	the	pathogens	mostly	cul-
tured	from	pretreatment	samples	were	Streptococcus uberis,	followed	by	Staphylococcus 
aureus	and	coagulase-	negative	staphylococci.	There	were	no	significant	differences	be-
tween	the	two	test	treatments	in	comparison	with	the	reference	treatment	regarding	all	
outcome	variables.	The	sole	therapy	with	Masti	Veyxym®	resulted	in	a	numerically	lower	
likelihood	of	BC	without	significant	differences	to	the	reference	treatment.	The	com-
bined	therapy	group	showed	a	numerically	higher	nonrecurrence	rate	than	the	two	other	
treatment	groups	and	noninferiority	compared	to	the	reference	treatment	was	proven.	
Having	regard	to	the	selection	criteria	of	cows	in	this	study,	the	findings	indicated	that	
sole	treatment	with	Masti	Veyxym®	in	nonsevere	CM	cases	may	constitute	an	alterna-
tive	therapy	to	reduce	antibiotics.	However,	noninferiority	evaluations	were	mostly	in-
conclusive.	Further	investigations	with	a	larger	sample	size	are	required	to	confirm	the	
results	and	to	make	a	clear	statement	on	noninferiority.
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution-NonCommercial	License,	which	permits	use,	distribution	and	reproduction	in	any	
medium,	provided	the	original	work	is	properly	cited	and	is	not	used	for	commercial	purposes.
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1  | INTRODUCTION
Clinical	mastitis	 (CM)	 is	 still	 a	 common	 and	 costly	 disease	 on	 dairy	
farms	all	over	the	world	(IDF	(International	Dairy	Federation),	2005;	
Hogeveen,	Huijps,	&	Lam,	2011).	The	treatment	method	of	choice	to	
combat	CM	is	antibiotic	therapy,	which	was	confirmed	by	a	recently	
conducted	multiherd	study	on	Dutch	dairy	farms.	Santman-	Berends,	
Lam,	Keurentjes,	and	van	Schaik	 (2015)	showed	that	 in	72%	of	CM	
cases,	 farmers	decided	to	use	antibiotic	 treatment.	Other	 investiga-
tions	conducted	in	51	large	dairy	herds	in	Wisconsin,	USA,	reported	
that	 95.4%	of	 cows	 suffering	 from	CM	were	 treated	with	 antibiot-
ics	(Oliveira	&	Ruegg,	2014).	This	results	in	high	usage	of	antibiotics,	
which	is	currently	publicly	discussed	due	to	the	problem	of	residuals	
and	potential	development	of	pathogen	resistances.	Cows	suffering	
from	CM	should	be	supplied	with	evidence-	based	 treatment	 to	en-
sure	 prudent	 use	 of	 antibiotics	 (Mansion-	de	Vries,	 Hoedemaker,	 &	
Krömker,	2015;	Ruegg,	2010)	because	it	 is	 impossible	to	prevent	all	
CM	cases.	Trevisi	et	al.	 (2014)	mentioned	 that	antibiotic	 treatments	
for	chronic	disease	cases	do	not	lead	to	increased	animal	health	and	
are	not	 reasonable	with	 regard	 to	 cost/benefit	 analysis.	The	aim	of	
antibiotic	therapy	must	be	considered	to	determine	the	benefit	of	an-
tibiotics	 for	 such	chronic	disease	cases.	Antibiotics	 are	only	able	 to	
combat	micro-	organisms.	Therefore,	the	success	is	assessed	by	bac-
teriological	cure	(BC)	and	is	defined	as	the	elimination	of	the	mastitis-	
causing	pathogen	from	the	infected	udder	quarter	(Krömker,	Paduch,	
Klocke,	 Friedrich,	 &	 Zinke,	 2010;	 Schukken	 et	al.,	 2013;	 Swinkels,	
Krömker,	&	Lam,	2014;	Ziesch	&	Krömker,	2016).	Many	studies	dealt	
with	the	influence	of	cow-	related	factors	on	the	BC	rate	of	CM	cases	
treated	with	antibiotics.	The	investigations	showed	a	decreasing	prob-
ability	of	BC	with	rising	amount	of	previous	CM	cases	in	the	same	lac-
tation	(Pinzón-	Sánchez	&	Ruegg,	2011;	Ziesch	&	Krömker,	2016)	and	
high	cow	somatic	cell	counts	 (CSCC)	prior	to	CM	(Bradley	&	Green,	
2009;	 Pinzón-	Sánchez	&	 Ruegg,	 2011;	 Sol,	 Sampimon,	 Barkema,	&	
Schukken,	 2000;	 Swinkels,	 Cox,	 Schukken,	 &	 Lam,	 2013;	 Ziesch	 &	
Krömker,	2016).	Consequently,	lowering	the	likelihood	of	BC	results	
in	declining	efficacy	and	usefulness	of	antibiotic	treatment.	Cows	with	
longer	lasting	udder	diseases	are	characterized	by	recurrent	CM	cases	
separated	by	periods	without	clinical	signs	and/or	constantly	elevated	
CSCC	defined	as	subclinical	mastitis	 (Grieger,	Zoche-	Golob,	Paduch,	
Hoedemaker,	&	Krömker,	2014;	GVA	[German	Veterinary	Association],	
2012).	With	the	help	of	the	aforementioned	cow-	related	factors,	CM	
history	in	the	current	lactation	and	persistent	elevation	in	CSCC,	we	
are	able	to	determine	cows	expecting	a	low	probability	of	BC	due	to	
antibiotic	treatment.	 If	possible	such	cows	should	be	removed	from	
the	herd	(Krömker	&	Friedrich,	2011)	or	in	the	case	of	CM	be	treated	
symptomatically	 to	 avoid	 useless	 application	 of	 antibiotics	 (Degen,	
Paduch,	 Hoedemaker,	 &	 Krömker,	 2015).	 From	 a	 farmer’s	 point	 of	
view,	such	cows,	especially	the	high-	yielding	animals,	are	still	profit-
able	as	long	as	they	show	no	clinical	signs	and	the	milk	is	saleable.	In	
the	case	of	CM,	a	 low	likelihood	of	BC	is	expected	from	a	scientific	
point	of	view.	Maybe	an	equal	clinical	cure	(CC)	rate	and	recurrence	
rate	during	the	further	course	of	lactation	in	comparison	with	an	anti-
biotic	treatment	could	possibly	convince	farmers	to	use	an	alternative	
therapy.	The	medicinal	product	Masti	Veyxym®	(Veyx-	Pharma	GmbH,	
Schwarzenborn,	Germany),	an	already	licensed	udder	injector	contain-
ing	ointment	for	intramammary	application	with	proteolytic	enzymes	
and	without	antibiotics,	could	be	a	useful	 treatment	option.	 In	vitro	
investigations	showed	an	inhibiting	activity	of	containing	proteolytic	
enzymes	against	udder	pathogens	(Krüger,	Hien,	Zaremba,	&	Penka,	
1999).	Zander	 (1997)	 conducted	a	clinical	 study	and	 reported	a	 re-
duction	 in	CSCC	due	to	sole	treatment	with	proteolytic	enzymes	of	
cows	with	bacteriologically	negative	subclinical	mastitis.	Furthermore,	
he	showed	a	higher	cure	rate	for	combined	treatment	with	antibiotics	
and	proteolytic	enzymes	than	solely	antibiotic	therapy	 in	cows	with	
chronic	mastitis	and	subclinical	mastitis	with	pathogen	detection.	 In	
addition	to	the	advantage	that	the	drug	does	not	contain	antibiotics,	
a	reduced	withdrawal	period	of	1	day	for	milk	and	zero	days	for	meat	
is	required	resulting	in	a	decrease	in	discarded	milk	and	an	increase	in	
revenue.	In	this	study,	we	compared	the	efficacy	of	the	test	product	
Masti	Veyxym®	to	antibiotic	treatment	as	reference	therapy.	Also,	a	
test	group	of	combined	antibiotic	and	Masti	Veyxym®	treatment,	sim-
ilar	to	the	investigations	of	Zander	(1997),	was	included	and	examined	
in	comparison	with	solely	antibiotic	treatment.	The	aim	of	the	study	
was	 to	 evaluate	 noninferiority	 of	 the	 test	 products	 against	 the	 ref-
erence	product	for	treatment	of	mild-	to-	moderate	CM	in	cows	with	
longer	lasting	udder	diseases.
2  | MATERIALS AND METHODS
2.1 | Study design
This	study	was	conducted	in	accordance	with	the	guidelines	on	good	
clinical	practice	(GCP;	EMEA	(The	European	Agency	for	the	Evaluation	
of	Medicinal	Products),	2000)	and	designed	as	a	noninferiority	study	to	
compare	two	test	treatment	groups	with	one	reference	treatment	group	
by	a	previously	defined	margin	of	noninferiority	(∆;	Piaggio,	Elbourne,	
Altman,	Pocock,	&	Evans,	2009;	O`Connor	et	al.,	2010;	Schukken	et	al.,	
2013).	The	null	hypothesis	implied	that	the	test	product	is	 inferior	to	
the	reference	product,	and	the	alternative	hypothesis	implied	that	the	
test	product	is	not	inferior	to	the	reference	product	regarding	the	de-
fined	margin	(−∆;	Piaggio	et	al.,	2009;	Schukken	et	al.,	2013):
H0:	[Poutcome(test)−Poutcome(reference)]≤−∆
HA:	[Poutcome(test)−Poutcome(reference)]>−∆
Whereby,	Poutcome	 is	the	probability	of	outcome	variables	for	the	
test	and	reference	product.	To	establish	noninferiority	of	a	test	prod-
uct	to	a	reference	product,	the	null	hypothesis	(H0)	must	be	discarded	
to	accept	the	alternative	hypothesis	(HA).	The	evaluations	of	possible	
study	results	that	were	described	by	Schukken	et	al.	(2013)	also	apply	
for	this	study.
2.2 | Sample size determination
Based	 on	 investigations	 of	 Schukken	 et	al.	 (2011),	 the	 margin	 of	
noninferiority	(∆)	was	determined	as	0.15	for	this	study.	Also,	other	
investigators	 recommended	 and	 applied	 this	 value	 for	 noninferi-
ority	margin	 in	CM	 studies	 (Deluyker,	Chester,	&	 van	Oye,	 1999;	
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Schukken	&	Deluyker,	1995;	Schukken	et	al.,	2013).	The	confidence	
interval	 (CI;	95%)	approach	was	used	to	calculate	required	sample	
size	based	on	the	clinical	cure	rate	and	CM	recurrence	rate.	In	this	
model,	 treatments	are	assumed	to	achieve	similar	cure	and	recur-
rence	rates	and	we	want	to	assure	on	the	95%	level	that	the	differ-
ence	is	not	higher	than	15%	regarding	the	margin	of	noninferiority	
and	the	null	effect.
If	there	 is	truly	no	difference	in	clinical	cure	rates	between	the	
reference	and	test	 treatment,	 then	37	CM	cases	per	group	are	 re-
quired	so	as	to	be	90%	sure	that	the	upper	limit	of	a	one-	sided	95%	
CI	 rules	out	a	difference	 in	 favour	of	 the	 reference	group	of	more	
than	15%.
If	there	is	truly	no	difference	in	recurrence	rates	between	the	ref-
erence	and	test	treatment,	then	50	CM	cases	per	group	are	required	
so	as	to	be	80%	sure	that	the	upper	limit	of	a	one-	sided	95%	CI	rules	
out	a	difference	in	favour	of	the	reference	group	of	more	than	15%.
Using	the	estimation	of	the	recurrences	due	to	the	higher	required	
sample	 size,	we	 calculated	 that	 if	 a	 further	 10%–15%	of	CM	 cases	
drop	out	of	the	study	postadmission,	around	60	cases	are	needed	per	
treatment	group.	Therefore,	a	total	of	180	cows	with	CM	have	to	be	
included.
2.3 | Inclusion criteria for farms and cows
Commercial	dairy	free-	stall	farms	with	interest	in	and	possibilities	for	
performing	the	study	were	eligible	for	inclusion.	Study	farms	have	to	
participate	in	the	German	Dairy	Herd	Improvement	(DHI)	programme,	
which	records	cow	data,	CSCC,	milk	yield	and	milk	 ingredients	on	a	
monthly	basis.
Every	 cow	must	 be	 registered	with	 a	 unique	 ear	 tag	 to	 clearly	
identify	every	animal,	as	stipulated	in	Germany.	Only	cows	that	have	
had	at	least	three	consecutively	high	CSCC	(>	400,000	somatic	cells/
ml)	 in	 the	 three	 previous	months	 and/or	 at	 least	 two	CM	 cases	 in	
the	current	lactation	directly	before	the	occurrence	of	the	CM	were	
admitted	for	inclusion	in	the	study.	Lactating	Holstein-	Friesian	dairy	
cows	of	all	parities	with	CM	signs	in	one	or	more	quarters	were	el-
igible	 for	 inclusion.	 Suitable	 cows	 showed	 a	 period	 of	 normal	milk	
secretion	without	signs	of	 inflammation	on	the	udder	quarters	until	
start	 of	 CM.	The	 subsequent	 clinical	 score	was	 used	 to	 character-
ize	and	determine	CM	at	occurrence.	A	quarter	was	classified	as	af-
fected	by	a	mild	CM	 if	 there	were	only	changes	 in	 the	appearance	
of	the	milk	(i.e.,	flaky	sediments,	watery	appearance,	discolouration).	
A	moderate	CM	showed	additionally	clinical	signs	of	mastitis	 in	the	
quarter	(i.e.,	swelling,	heat,	pain,	redness)	with	or	without	changes	in	
milk	secretion	as	previously	described.	A	CM	was	classified	as	severe	
when	a	cow	suffered	from	general	clinical	signs	of	disease	(i.e.,	fever	
(rectal	temperature	>39.5°C),	dehydration,	anorexia,	depression)	with	
or	without	deviations	of	the	milk	and/or	the	udder	quarter	(Pinzón-	
Sánchez	&	Ruegg,	2011;	Swinkels	et	al.,	2014).	Cows	were	excluded	
from	the	study	if	they	showed	significant	udder,	teat	or	teat	orifice	
lesions,	suffered	from	severe	CM	cases,	had	been	treated	with	other	
products	in	addition	to	the	mastitis	treatment	or	had	concurrent	dis-
eases	at	the	time	of	CM.
2.4 | Treatment and randomisation
Treatment	was	applied	by	instructed	farm	staff.	Three	different	treat-
ment	regimens	were	investigated	in	the	study:	group	1)	AB,	antibiotic	
treatment	as	usual	on	 the	 farm	according	 to	 label	of	 the	 respective	
product;	 group	2)	ABMV,	antibiotic	 treatment	as	usual	on	 the	 farm	
according	 to	 label	 of	 the	 respective	 product	 combined	 with	 Masti	
Veyxym®	 (Veyx-	Pharma	GmbH,	Schwarzenborn,	Germany)	compris-
ing	 three	 treatments	 of	 10-	g	 disposable	 syringe	 containing	 120	mg	
α-	tocopherol	 acetate,	 58.83	mg	 retinol	 palmitate,	 2,400	 FIP-	U	 chy-
motrypsin,	240	FIP-	U	 trypsin	 and	6	FIP-	U	papain	per	 syringe	at	 an	
interval	of	12	hr;	and	group	3)	MV,	solely	Masti	Veyxym®	comprising	
three	treatments	at	an	interval	of	12	hr.	All	affected	quarters	of	cows	
in	the	AB	and	ABMV	treatment	groups	received	intramammary	antibi-
otic	therapy,	and	if	desired	additionally,	a	systemic	antibiotic	therapy	
was	allowed.
For	treatment	allocation,	cows	were	grouped	by	lactation	number	
(1,	>1).	In	every	lactation	number	group,	cows	fulfilling	the	inclusion	
criteria	were	randomly	allocated	to	a	treatment	group	based	on	a	ran-
domization	list	and	therapy	applied	following	strict	asepsis	by	trained	
farm	personnel.	Every	farm	had	its	own	randomization	list	which	was	
structured	 in	 the	 following	way,	 the	 first	 affected	 cow	meeting	 the	
inclusion	criteria	was	assigned	to	the	treatment	group	AB,	the	second	
cow	was	allocated	 to	 the	 treatment	group	ABMV,	 the	 third	cow	re-
ceived	solely	Masti	Veyxym®,	and	the	fourth	cow	commenced	again	
with	the	treatment	group	AB	and	so	on.	Cows	with	CM	in	more	than	
one	quarter	were	also	eligible	for	inclusion	in	the	study,	and	all		affected	
quarters	received	the	same	therapy.
2.5 | Flow of events for a cow in the study
Every	month,	a	list	containing	eligible	cows	from	every	farm	was	pre-
pared	by	the	first	author	(MZ)	based	on	the	monthly	DHI	results	and	
the	farm	records	of	cow	CM	history.	Farm	staff	was	 instructed	and	
trained	to	perform	mastitis	identification,	clinical	data	collection,	sam-
pling,	treatment	and	to	fill	in	treatment	protocols	in	accordance	with	
the	study	procedure.	A	cow	with	a	mild	or	moderate	CM	case	in	one	
or	more	quarters	was	identified	by	the	milkers	and	checked	for	suit-
ability	of	inclusion	in	the	study	using	the	list	of	eligible	cows.	When	
a	cow	fulfilled	the	inclusion	criteria,	the	cow	was	allocated	to	one	of	
the	 three	 treatment	groups	 in	accordance	with	 the	aforementioned	
randomization	list.	Before	aseptic	application	of	treatment,	a	foremilk	
sample	of	the	affected	quarter	was	taken	by	trained	milkers	respect-
ing	the	guidelines	of	aseptic	milk	sampling	(GVA	[German	Veterinary	
Association],	2009).	Treatment	was	performed	according	to	the	label	
of	 the	 respective	 product.	 In	 the	 combined	 therapy	 group	 (ABMV),	
first	 the	 antibiotic	 and	 immediately	 afterwards	 the	Masti	 Veyxym® 
were	 injected.	At	 every	milking	 period,	 the	 clinical	 score	 of	 the	 af-
fected	quarter	was	assessed	by	the	milkers	until	7	days	after	the	end	
of	 treatment.	 When	 clinical	 signs	 deteriorated,	 the	 farmer	 was	 al-
lowed	to	treat	the	cow	with	an	additional	or	different	treatment	and	
the	case	was	documented	as	treatment	failure.	CM	cases	where	the	
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clinical	signs	disappeared	until	day	7	after	the	end	of	treatment	and	
without	classification	as	treatment	failure	were	assessed	as	clinically	
cured.	 These	 cured	 quarters	 were	 observed	 from	 day	 8	 to	 day	 60	
after	 the	end	of	 treatment	 for	 recurrent	CM	cases,	 and	 in	 the	case	
of	recurrence,	a	quarter	foremilk	sample	was	collected.	Furthermore,	
instructed	farm	staff	took	quarter	foremilk	samples	at	day	14	(±2)	and	
day	21	(±2)	after	the	end	of	treatment	of	all	clinically	cured	quarters.	
Milk	samples	were	stored	in	the	on-	farm	refrigerators	and	picked	up	
once	a	week	by	the	first	author.	During	these	regular	farm	visits,	the	
first	author	exchanged	information	with	the	herd	personnel	to	resolve	
inaccuracies	and	ensure	data	quality.	Any	deviations	from	the	study	
protocol	were	noted	and	investigated	for	eligibility	to	include	in	the	
study.	 Commonly	 used	 cow-	level	 data	 including	 lactation	 number,	
affected	quarter	 location,	milk	yield,	CSCC	of	the	three	most	recent	
DHI	 recordings	 prior	 to	 CM,	 days	 in	milk	 (DIM)	 at	 CM	 occurrence	
and	concurrent	diseases	and	treatments	for	a	period	of	30	days	after	
	enrolment	were	recorded.
2.6 | Blinding
It	was	not	possible	to	blind	either	the	study	personnel	or	the	farmers/
herdspersons	to	product	administration	by	virtue	of	 the	differences	
in	treatment	regimens.	The	personnel	at	the	laboratory	culturing	for	
mastitis	pathogens	was	unaware	of	the	treatment	given	to	the	quarter	
being	sampled.
2.7 | Laboratory procedure
All	milk	samples	were	collected	aseptically	and	were	stored	below	
8°C	until	analysis.	Ly20,	containing	boric	acid	as	preserving	agent,	
was	 used	 in	 test	 tubes	 (GVA	 [German	 Veterinary	 Association],	
2009).	The	samples	were	sent	to	the	microbiological	 laboratory	at	
the	University	of	Applied	Sciences	and	Arts	Hannover	 (Germany).	
Microbiological	 examinations	were	 performed	 in	 accordance	with	
the	guidelines	of	the	German	Veterinary	Association	(GVA	[German	
Veterinary	 Association],	 2009),	 which	 are	 based	 on	 National	
Mastitis	 Council	 recommendations	 (NMC	 (National	 Mastitis	
Council),	 1999);	 10	μl	 of	 each	milk	 sample	was	plated	on	 a	quad-
rant	 of	 an	 aesculin	 blood	 agar	 plate	 (Oxoid,	 Germany)	 and	 incu-
bated	at	 least	 for	48	hr	 at	37°C	under	 aerobic	 conditions.	By	 the	
assessment	of	Gram	staining,	morphology	of	the	colonies	and	cells,	
hemolysis	patterns,	aesculin	hydrolysis	and	activity	of	catalase	(3%	
H2O2;	Merck,	Germany),	an	initial	evaluation	of	the	grown	colonies	
was	performed.	Subsequently,	several	biochemical	tests	were	per-
formed	 to	 determine	 the	 growing	micro-	organisms.	 The	 clumping	
factor	test	(DiaMondiaL	Staph	Plus	Kit,	Sekisui	Virotech,	Germany)	
instead	of	the	coagulase	test	was	used	to	differentiate	presumptive	
Staphylococcus	 (S.)	 aureus	 from	 coagulase-	negative	 staphylococci	
(CNS).	Different	aesculin-	negative	streptococci	were	distinguished	
by	the	serological	tests	for	Lancefield	Group	B	(Streptococcus (Sc.) 
agalactiae),	 C	 (Sc. dysgalactiae)	 and	 G	 (DiaMondiaL	 Streptococcal	
Extraction	 Kit	 Sekisui	 Virotech,	 Germany).	 To	 differentiate	 be-
tween	Sc. uberis and Enterococcus	spp.,	the	modified	Rambach	agar	
according	 to	Watts,	 Salmon,	 and	Yancey	 (1993)	was	 used.	Gram-	
positive,	 beta-	haemolytic	 and	 catalase-	negative	 irregular	 rods	
with	 a	V-	or	Y-	shaped	 configuration	were	 identified	 as	Trueperella 
(T.) pyogenes.	 Coryneform	 bacteria	 form	 small	 colonies	 on	 aes-
culin	 blood	 agar.	 They	 are	 gram-	positive	 and	 catalase-	positive.	
Both	T. pyogenes	 and	 coryneform	 bacteria	 are	 asporogen.	Bacillus 
spp.	 form	 large	 colonies	 on	 aesculin	 blood	 agar.	Bacillus	 spp.	 are	
gram-	positive,	 catalase-	positive	 rods	 and	 can	 form	 endospores.	
Coliform	 bacteria	 are	 gram-	negative,	 catalase-	negative	 and	 cy-
tochrome	 oxidase-	negative	 (Bactident	 oxidase,	 Merck,	 Germany)	
rod-	shaped	 bacteria,	 which	 can	 metabolize	 glucose	 fermenta-
tively	 (OF	 basal	 medium	with	 addition	 of	 D	 (+)-	glucose	monohy-
drate,	 Merck,	 Germany).	 On	 Chromocult	 Coliform	 Agar	 (Merck,	
Germany),	 Escherichia	 (E.)	 coli	 forms	 blue	 colonies	 under	 aerobic	
incubation	 at	 37°C	 for	 24	hr,	 and	 other	 coliforms	 form	 pink-	red	
colonies.	Klebsiella	spp.	are	immobile	during	the	performance	of	the	
OF	test.	Pseudomonads	were	identified	as	gram-	negative,	catalase-	
positive	and	cytochrome	oxidase-	positive	rod-	shaped	bacteria	that	
break	down	glucose	oxidatively.	Yeasts,	moulds	and	Prototheca	spp.	
were	differentiated	microscopically	after	subculturing	on	YGC	agar	
(Merck,	Germany).	Environment-	associated,	mastitis-	causing	micro-	
organisms	(Sc. uberis,	E. coli,	CNS,	Klebsiella	spp.,	coliform	bacteria,	
yeasts,	Pseudomonas	spp.	and	Prototheca	spp.)	were	recorded	as	a	
microbiologically	positive	result	if	≥5	cfu/0.01	ml	were	cultured	to	
reduce	bias	due	to	contamination.	If	two	pathogens	were	cultured,	
the	case	was	included	in	the	study	and	both	micro-	organisms	were	
documented.	A	milk	sample	was	considered	as	contaminated	when	
more	 than	 two	pathogens	were	 identified,	 except	 in	 cases	where	
also	 S. aureus,	 Sc. agalactiae,	 Sc. dysgalactiae and T. pyogenes were 
cultured.	Then,	only	the	growth	of	these	pathogens	was	recorded,	
and	the	cases	were	classified	as	contaminated	if	the	samples	con-
tained	more	 than	 two	of	 these	pathogens.	 The	Somascope	Smart	
(Delta	 Instruments,	 The	 Netherlands)	 was	 used	 to	 determine	 the	
quarter	SCC	(QSCC)	by	flow	cytometry.
2.8 | Outcome variables
Primary	 outcomes	 were	 clinical	 cure	 (CC)	 and	 no	 CM	 recurrence	
within	60	days	after	the	end	of	treatment	 (no	R60).	Secondary	out-
comes	were	bacteriological	cure	(BC)	and	quarter	somatic	cell	count	
(QSCC)	cure.	clinical	cure	(CC)	was	defined	as	the	absence	of	clinical	
signs	in	milk,	this	means	without	flaky	sediments,	watery	appearance	
or	discolouration	and	on	udder	quarter,	this	means	without	swelling,	
heat,	redness	or	pain	at	days	5–7	after	the	end	of	treatment.	Clinical	
mastitis	 (CM)	 cases	 of	 cows	which	 received	 additional	 or	 different	
treatment	due	to	deterioration	of	clinical	score	within	the	7	days	after	
the	end	of	initial	therapy	or	were	removed	from	the	herd	due	to	udder	
disease	were	assessed	as	failure	of	CC.
Quarters	with	clinically	cured	cases	were	observed	for	 the	time	
frame	of	day	8	to	day	60	after	the	end	of	treatment	and	defined	as	
recurrent	 quarters	when	 one	 or	more	 CM	 cases	were	 detected.	A	
quarter	showed	no	R60	if	it	was	free	of	CM	within	the	observed	time	
frame.
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Bacteriological	 cure	 was	 defined	 as	 the	 absence	 of	 the	
pathogen-	cultured	 pretreatment	 in	 both	 post-	treatment	 samples	
at	days	14	and	21.	If	a	bacterial	species	other	than	the	pathogen-	
cultured	pretreatment	was	isolated	in	the	post-	treatment	samples,	
the	 case	was	 still	 defined	 as	 bacteriologically	 cured.	 In	 case	 one	
post-	treatment	 sample	 was	 contaminated,	 the	 outcome	 of	 the	
other	post-	treatment	sample	was	used	to	determine	the	BC.	If	two	
pathogens	were	isolated	in	the	pretreatment	sample,	the	case	was	
enrolled	 as	mixed	 infection	 and	applied	 as	bacteriologically	 cured	
if	neither	of	the	two	pathogens	were	cultured	in	both	of	the	post-	
treatment	samples.	When	a	clinically	cured	quarter	suffered	from	a	
CM	recurrence	within	day	8	to	day	21	after	the	end	of	treatment,	
available	post-	treatment	samples	and	the	recurrence	sample	were	
used	to	determine	BC.
QSCC	 cure	was	 defined	 as	 a	QSCC	 being	 <200,000	 cells/ml	 in	
both	 post-	treatment	 samples	 at	 days	 14	 and	 21.	 In	 case	 one	 post-	
treatment	sample	was	missing,	the	QSCC	of	the	other	post-	treatment	
sample	was	used	to	determine	the	outcome.	When	a	clinically	cured	
quarter	suffered	from	a	CM	recurrence	within	day	8	to	day	21	after	
the	end	of	treatment,	the	CM	case	was	assessed	as	failure	of	QSCC	
cure.	Quarters	with	CM	cases	experiencing	no	CC	were	also	included	
in	the	analysis	as	failure	of	BC	and	QSCC	cure	to	take	the	principle	
of	“intention-	to-	treat”	into	account	(O`Connor	et	al.,	2010;	Schukken	
et	al.,	2013).
2.9 | Statistical analysis
The	 data	 were	 collected	 and	 analysed	 using	 Excel,	 Office	 2010	
(Microsoft	 Corporation)	 and	 SPSS	 (IBM	 SPSS	 23.0.0.0,	 Armonk,	
USA).	 The	 statistical	 unit	 was	 the	 CM	 case	 of	 an	 udder	 quarter.	
For	every	CM	case,	CC	or	no	CC,	R60	or	no	R60,	BC	or	no	BC	and	
QSCC	cure	or	no	QSCC	cure	(encoded	as	1	or	0,	respectively)	were	
determined	according	to	the	aforementioned	definitions,	constitut-
ing	 the	binary	dichotomous-	dependent	variables.	Outcomes	were	
analysed	using	generalized	linear	mixed	models	including	lactation	
number,	 DIM	 and	 pathogen-	cultured	 pretreatment	 as	 important	
covariates.	As	clustering	was	present	in	the	design	(i.e.,	gland	within	
cow	and	cow	within	herd),	the	analysis	was	corrected	using	random	
effects,	 but	 had	 no	 relevant	 influence.	 The	 treatment	 group	was	
the	main	variable	of	 interest.	Statistical	 significance	was	assumed	
at	α = 0.05.
The	linear	predictor	was	calculated	as
Logit	(outcome)	=	intercept	+	treatment	+	lactation	number	+	DIM	
+	pathogen	+	herd	*	cow	*	gland	(random).
CC,	 no	R60,	BC	or	QSCC	are	 the	outcomes	 and	 lactation	 num-
ber	is	the	lactation	number	of	the	included	cow	grouped	as	1,	2	and	
over	2.	DIM	is	days	in	milk	of	the	cow	at	CM	occurrence	grouped	as	
0–100,	101–200	and	over	200.	Pathogen-	cultured	pretreatment	were	
grouped	 into	 Enterobacteriaceae,	 streptococci,	 staphylococci,	 other	
pathogens,	contaminated	samples	and	no	growth.
For	CC,	no	R60	and	BC,	 the	model	was	used	 to	calculate	 least-	
square	means	 of	 the	various	 treatment	 groups.	Thereby,	 the	 differ-
ences	 between	 treatments	 were	 estimated.	 Confidence	 intervals	
of	 the	 therapy	differences	were	 calculated	utilising	 the	 least-	square	
means	and	the	standard	deviation	(Schukken	et	al.,	2013).
3  | RESULTS
3.1 | Descriptive results
The	time	frame	for	data	collection	ranged	from	September	2014	to	
September	2015.	The	study	was	conducted	on	eight	free-	stall	dairy	
farms	located	in	Eastern	Germany.	All	farms	were	conventional	and	
commercially	oriented	with	a	herd	size	between	approximately	140	
and	 800	 lactating	 Holstein-	Friesian	 dairy	 cows.	 The	 milk	 produc-
tion	ranged	from	8,000	and	9,700	kg/cow/year	with	bulk	milk	SCC	
(BMSCC)	 between	 181,000	 and	 382,000	 cells/ml.	 All	 farms	 were	
equipped	with	modern	milking	 systems	and	used	common	hygiene	
management	methods.	Milkers	wore	gloves	during	milking,	used	one	
tissue	per	cow	to	clean	the	teats	before	milking	and	utilized	teat	dis-
infection	after	milking.	All	herds	were	milked	twice	a	day,	except	on	
one	 farm	where	 the	high-	yielding	and	fresh	cow	group	was	milked	
three	times	a	day.	A	rotary	milking	parlour	was	installed	on	five	farms,	
three	farms	milked	with	a	herringbone	parlour	and	no	automatic	milk-
ing	system	was	present.	All	cows	were	fed	with	total	mixed	rations.
In	total,	174	CM	cases	were	enrolled	in	the	study	and	no	adverse	
events	of	treatment	were	observed.	The	median	of	lactation	number	
for	all	CM	cases	amounted	to	2	(minimum	1;	maximum	6),	of	CSCC	
last	DHI	before	CM	onset	594,000	cells/ml	(minimum	16,000	cells/
ml;	maximum	9,694,000	 cells/ml)	 and	of	milk	yield	 last	DHI	before	
CM	occurrence	30.15	kg	(minimum	10.3	kg;	maximum	58.4	kg).	In	89	
cases	 the	 front	quarters	and	 in	85	cases	 the	 rear	quarters	 suffered	
from	CM.	The	 severity	of	 clinical	 signs	 at	CM	case	occurrence	was	
classified	as	mild	in	106	cases	and	as	moderate	in	68	cases.	A	propor-
tion	of	26.4%	of	the	CM	cases	arose	in	cows	being	0–100	days	in	milk	
(DIM),	40.3%	being	101–200	DIM	and	33.3%	being	over	200	DIM,	
respectively.	Solely,	antibiotic	 treatment	 (AB)	was	applied	 in	59	CM	
cases,	63	quarters	received	combined	treatment	(ABMV)	and	solely,	
Masti	Veyxym®	 (MV)	was	used	 in	52	CM	cases.	Consequently,	122	
quarters	were	treated	with	antibiotics,	the	used	ingredients	of	which	
are	shown	in	Table	1.	Thereof,	74.6%	of	quarters	suffering	from	CM	
TABLE  1 Number	and	percentage	of	the	used	antibiotic	
ingredients	for	clinical	mastitis	(CM)	treatment	in	the	study
Antibiotic ingredients
Number of treated 
CM cases (%)
Cefquinome 57/122	(46.7)
Ampicillin,	Cloxacillin 25/122	(20.5)
Cefoperazone 20/122	(16.4)
Cefalexin,	Kanamycin 5/122	(4.1)
Procaine	benzylpenicillin 4/122	(3.3)
Lincomycin,	Neomycin 3/122	(2.5)
Cefalexin 1/122	(0.8)
Mixed	ingredients 7/122	(5.7)
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received	solely	intramammary	antibiotic	therapy,	and	in	25.4%	of	CM	
cases,	combined	intramammary	and	systemic	antibiotic	treatment	was	
applied.
Foremilk	samples	of	the	affected	quarters	at	CM	occurrence	were	
available	in	169	cases,	the	remaining	five	samples	forgotten	to	be	taken	
by	the	milkers.	The	results	of	bacteriological	culture	are	presented	in	
Table	2.	The	pathogen	mostly	cultured	from	the	pretreatment	sample	
was	Sc. uberis	(14.2%),	followed	by	S. aureus	(11.8%),	and	CNS	(9.5%),	
respectively.	No	micro-	organisms	were	cultured	in	28	cases	(16.6%),	
26	quarters	showed	mixed	infections	(15.4%)	and	four	samples	were	
contaminated	(2.3%).	In	53.8%	of	the	mixed	infections,	Sc. uberis	was	
one	of	the	cultured	pathogens,	and	in	30.8%,	S. aureus	was	one	of	the	
isolated	micro-	organisms.
3.2 | Homogeneity of treatment groups
No	 significant	 differences	 between	 treatment	 groups	 in	 DIM	 and	
pathogen-	cultured	 pretreatment	were	 found	 (p > .2).	 Treatment	was	
allocated	at	herd	 level	 and	at	 the	 lactation	number	 level	 grouped	 in	
lactation	number	1	and	>1.	For	good	measure,	herd	as	random	effect,	
DIM,	lactation	number	and	pathogen-	cultured	pretreatment	were	in-
cluded	in	the	generalized	linear	mixed	models	to	take	these	factors	into	
account.
3.3 | Clinical cure
The	overall	CC	rate	was	62.6%	(109/174).	The	probability	of	CC	in	the	
AB	group	was	62.7%	(37/59),	in	the	ABMV	group	63.5%	(40/63)	and	
in	the	MV	group	61.5%	(32/52),	respectively.
Results	of	the	generalized	linear	mixed	model	showed	least-	square	
means	of	63.8%	 for	 the	AB	group,	62.2%	 for	 the	ABMV	group	and	
58.3%	 for	 the	MV	group.	However,	no	 significant	differences	 in	CC	
of	the	reference	treatment	AB	to	the	test	treatment	MV	(p = .61)	and	
to	 the	 test	 treatment	ABMV	 (p = .875)	were	 found	 (Table	3).	 Cows	
suffering	 from	 CM	 within	 101–200	 DIM	 showed	 a	 significantly	
lower	probability	of	CC	than	cows	affected	with	CM	over	200	DIM	
(p = .023).	The	point	estimate	of	the	calculated	differences	in	CC	from	
the	logistic	regression	and	the	associated	95%	CI	is	shown	in	Figure	1.	
Noninferiority	is	inconclusive	for	both	test	treatments	in	comparison	
with	the	reference	treatment.
3.4 | No recurrence 60 days
Only	quarters	with	clinically	cured	cases	of	cows,	which	were	still	in	
milk	60	days	after	 the	end	of	 treatment,	were	 included	 in	this	anal-
ysis	 (Pinzón-	Sánchez	 &	 Ruegg,	 2011).	 Of	 the	 109	 clinically	 cured	
quarters,	23	cases	were	excluded	because	the	cow	had	been	dried-	
off	 (13	cases)	or	 sold	 (ten	 cases)	within	 the	 considered	 time	 frame.	
Consequently,	86	CM	cases	were	included	in	the	analysis.	The	overall	
no	R60	rate	was	58.1%	(50/86).	The	probability	of	achieving	no	CM	
recurrence	within	60	days	after	the	end	of	treatment	in	the	AB	group	
was	53.6%	(15/28),	in	the	ABMV	group	65.7%	(23/35)	and	in	the	MV	
group	52.2%	(12/23),	respectively.
Results	of	the	generalized	linear	mixed	model	showed	numerically	
different	least-	square	means	of	66.8%	for	the	AB	group,	88.2%	for	the	
ABMV	group	and	55.6%	for	the	MV	group.	However,	no	significant	dif-
ferences	in	no	R60	of	the	reference	treatment	AB	to	the	test	treatment	
MV	(p = .556)	and	to	the	test	treatment	ABMV	(p = .087)	were	found	
(Table	4).	Cows	suffering	from	CM	in	the	first	lactation	(p = .026)	and	in	
the	second	lactation	(p = .009)	showed	a	significantly	higher	probability	
of	no	R60	than	cows	affected	with	CM	in	the	third	or	higher	lactation.	
Furthermore,	 animals	 contracting	 CM	 over	 200	 DIM	 had	 a	 signifi-
cantly	higher	 likelihood	of	no	R60	compared	 to	cows	suffering	 from	
CM	within	0–100	DIM	(p = .009)	and	cows	affected	with	CM	within	
101–200	DIM	(p = .043).	CM	cases	caused	by	staphylococci	showed	
a	 significantly	 lower	probability	of	no	R60	 than	CM	cases	where	no	
pathogen	was	cultured	pretreatment	(p = .048).	The	point	estimate	of	
the	calculated	differences	in	no	R60	from	the	logistic	regression	and	
the	associated	95%	CI	is	shown	in	Figure	1.	Noninferiority	is	inconclu-
sive	for	the	MV	treatment	in	comparison	with	the	AB	treatment.	The	
ABMV	therapy	is	noninferior	to	the	AB	therapy.
3.5 | Bacteriological cure
Bacteriological	cure	was	determined	for	129	CM	cases.	The	remaining	
45	cases	were	excluded	because	of	growth-	negative	(28	cases),	miss-
ing	(five	cases)	or	contaminated	(four	cases)	pretreatment	samples	and	
TABLE  2 Bacteriological	culture	results	of	the	169	clinical	
mastitis	(CM)	pretreatment	samples
Micro- organism Number %
Enterobacteriaceae 8
Coliforms	(other	than	Escherichia coli 
and Klebsiella	spp.)
5 3.0
Escherichia coli 3 1.8
Streptococci 35
Streptococcus uberis 24 14.2
Streptococcus dysgalactiae 8 4.7
Other	streptococci 3 1.8
Staphylococci 36
Staphylococcus aureus 20 11.8
Coagulase-	negative	staphylococci	(CNS) 16 9.5
Other	pathogens 32
Coryneforms 12 7.1
Pseudomonas	spp. 7 4.1
Prototheca	spp. 5 3.0
Enterococci 4 2.3
Trueperella pyogenes 3 1.8
Yeasts 1 0.6
No	growth 28 16.6
Mixed	infections 26 15.4
Contaminated 4 2.3
Total 169 100
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missing	post-	treatment	samples	(eight	cases).	The	overall	BC	rate	was	
34.9%	 (45/129).	The	probability	of	BC	 in	 the	AB	group	was	37.2%	
(16/43),	 in	 the	 ABMV	 group	 39.1%	 (18/46)	 and	 in	 the	 MV	 group	
27.5%	(11/40),	respectively.
Results	of	 the	generalized	 linear	mixed	model	showed	the	 least-	
square	means	of	38.2%	for	the	AB	group,	31.6%	for	the	ABMV	group	
and	20.9%	for	the	MV	group.	However,	no	significant	differences	 in	
BC	of	the	reference	treatment	AB	to	the	test	treatment	MV	(p = .151)	
and	 to	 the	 test	 treatment	 ABMV	 (p = .570)	 were	 found	 (Table	5).	
Cows	suffering	from	CM	within	101–200	DIM	showed	a	significantly	
lower	probability	of	BC	than	cows	affected	with	CM	over	200	DIM	
(p = .002).	The	point	estimate	of	the	calculated	differences	in	BC	from	
the	logistic	regression	and	the	associated	95%	CI	is	shown	in	Figure	1.	
Noninferiority	is	inconclusive	for	both	test	treatments	in	comparison	
with	the	reference	treatment.
3.6 | Quarter somatic cell count cure
Overall	 twelve	 CM	 cases	 were	 excluded	 from	 this	 analysis	 due	 to	
missing	post-	treatment	samples	(seven	cases)	or	the	cow	was	dried-	
off	 (three	 cases)	 or	 slaughtered	 (one	 case)	 or	 suffered	 from	 a	 teat	
injury	(one	case)	before	at	least	the	first	post-	treatment	sample	was	
collected.	The	pretreatment	CSCC	and	 the	course	of	QSCC	 for	 the	
examined	treatment	groups	are	shown	in	Table	6.	The	overall	QSCC	
cure	was	9.88%	(16/162).	 Including	the	 important	covariates	of	 the	
aforementioned	generalized	linear	mixed	model,	there	are	no	signifi-
cant	differences	between	the	 investigated	treatment	groups	for	the	
outcome	variable	QSCC	cure	(p = .159;	data	not	shown).
4  | DISCUSSION
The	main	aim	of	this	study	was	to	evaluate	the	efficacy	of	a	nonanti-
biotic	intramammary	treatment	with	Masti	Veyxym®	(MV)	in	compari-
son	with	a	reference	therapy	with	antibiotics	(AB)	of	nonsevere	CM	
in	cows	with	longer	lasting	udder	diseases.	Furthermore,	the	influence	
of	Masti	Veyxym®	on	the	efficacy	of	antibiotic	treatment	for	such	CM	
cases	was	 investigated	by	 inclusion	of	a	combined	 treatment	group	
(ABMV).
Regarding	CC	as	one	primary	outcome,	descriptive	results	showed	
small	differences	in	cure	rates	ranging	from	62.7%	for	the	reference	
treatment	 (AB)	to	63.5%	for	ABMV	and	61.5%	for	the	nonantibiotic	
treatment.	This	is	in	accordance	with	further	investigations,	which	re-
ported	a	probability	of	CC	of	approximately	60%	for	CM	cases	treated	
with	antibiotics,	respecting	different	definitions	of	CC	(Schukken	et	al.,	
2013;	 Swinkels	 et	al.,	 2014).	 The	 small	 variations	 in	 CC	 rates	were	
Variable
Coefficient
OR 95% CI p- valueaX SE
Intercept −0.399 0.594 0.671 0.206–2.189 .504
Treatment
MV 0.231 0.451 1.260 0.513–3.093 .610
ABMV 0.069 0.440 1.072 0.446–2.574 .875
AB	(reference) 0
Lactation	number	of	the	cow	at	the	day	of	clinical	mastitis	occurrence
1 0.256 0.448 1.291 0.529–3.151 .570
2 0.182 0.404 1.199 0.537–2.680 .654
>2	(reference) 0
Days	in	milk	at	the	day	of	clinical	mastitis	occurrence
0–100 −0.433 0.460 0.649 0.260–1.620 .349
101–200 −0.959 0.414 0.383 0.168–0.873 .023
>200	(reference) 0
Pathogen	cultured	from	the	pretreatment	milk	sample
Enterobacteriaceae 0.813 0.917 2.254 0.363–13.984 .378
Streptococci 0.714 0.559 2.043 0.672–6.209 .205
Staphylococci 0.082 0.580 1.086 0.342–3.441 .888
Other	pathogens −0.178 0.540 0.837 0.286–2.454 .743
Contaminated	
sample
−0.530 1.304 0.589 0.044–7.882 .686
No	growth	
(reference)
0
aSignificance	set	at	p < .05.	Bold	value	indicates	significant	value.
TABLE  3 Final	mixed	logistic	regression	
model	results	for	the	primary	outcome	
variable	clinical	cure.	Three	different	
treatment	regimens	were	investigated:	MV,	
solely	Masti	Veyxym®,	comprising	three	
treatments	at	an	interval	of	12	hr;	ABMV,	
antibiotic	treatment	as	usual	on	the	farm	
according	to	label	of	the	respective	
product	combined	with	Masti	Veyxym®,	
comprising	three	treatments	at	an	interval	
of	12	hr;	AB,	antibiotic	treatment	as	usual	
on	the	farm	according	to	label	of	the	
respective	product
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confirmed	by	statistical	analysis,	showing	no	significant	differences	for	
the	two	test	treatments	in	comparison	with	the	reference	treatment	
(Table	3).	Noninferiority	was	inconclusive,	because	the	CI	spans	both	
the	noninferiority	margin	(−∆)	and	0	(Figure	1).	An	inconclusive	result	
could	possibly	occur	due	to	a	wide	range	of	the	CI.	A	method	to	reduce	
this	 range	 is	 to	 increase	 sample	 size.	The	noninferiority	margin	 also	
influences	 the	 outcome	 and	was	 chosen	 according	 to	 previous	 CM	
trials	 (Deluyker	 et	al.,	 1999;	 Schukken	&	Deluyker,	 1995;	 Schukken	
et	al.,	2013).	Sample	size	was	calculated	to	give	the	study	sufficient	
power	and	to	show	a	difference	between	test	and	reference	therapy	
if	there	was	a	real	difference	of	at	 least	15%	according	to	Schukken	
et	al.	 (2013).	 The	 nonantibiotic	 treatment	 showed	 a	 numerically	 al-
most	identical	CC	rate	and	no	significant	differences	to	the	reference	
treatment;	noninferiority	was	inconclusive	due	to	the	lack	of	power.
The	 other	 primary	 outcome	 variable	was	 no	 R60.	 The	 probabil-
ity	 of	 achieving	 no	 CM	 recurrence	 within	 60	days	 after	 the	 end	 of	
treatment	was	 almost	 numerically	 identical	 for	 AB	 (53.6%)	 and	MV	
(52.2%).	Statistical	analysis	showed	no	significant	differences	between	
these	two	treatments.	Noninferiority	was	inconclusive	because	the	CI	
showed	a	very	wide	range	and	spans	−∆	and	0.	Recurrences	were	ob-
served	only	for	clinically	cured	cases,	and	some	cows	dropped	out	due	
to	 the	 fact	 that	 they	were	not	 in	milk	until	60	days	after	 the	end	of	
treatment.	Hence,	the	amount	of	evaluable	cases	was	low	and	the	CI	in-
creased.	The	no	R60	rate	of	ABMV	(65.7%)	was	numerically	better	than	
the	rate	of	the	reference	product;	only	a	tendency	but	no	significant	
differences	was	shown	(p = .087;	Table	4).	The	CI	of	the	difference	be-
tween	these	two	treatments	spanned	only	0;	thus,	ABMV	is	noninferior	
to	the	solely	antibiotic	therapy	(Figure	1).	In	a	previous	study,	Pinzón-	
Sánchez	and	Ruegg	(2011)	reported	an	overall	nonrecurrence	rate	of	
approximately	80%	within	60	days.	That	value	is	much	higher	than	the	
overall	no	R60	rate	of	this	study	(58.1%),	although	they	used	the	recur-
rence	definition	on	cow	level	expecting	actually	a	lower	nonrecurrence	
rate	in	contrast	to	the	quarter	level	used	in	this	study.	A	reason	could	
be	that	 in	 this	study,	only	cows	with	a	 longer	 lasting	high	CSCC	and	
with	previous	CM	cases	were	included.	CM	is	a	disease	with	recurrent	
character	(Schukken,	Bar,	Hertl,	&	Gröhn,	2010),	and	Cha	et	al.	(2016)	
showed	that	a	cow	with	two	CM	cases	in	current	lactation	had	a	higher	
risk	of	contracting	a	third	case.	Therefore,	the	low	overall	no	R60	rate	
could	be	an	indication	that	the	used	eligibility	criteria	are	able	to	select	
cows	with	a	higher	recurrence	rate	as	previously	intended.
Bacteriological	 cure	was	 investigated	as	 secondary	outcome	be-
cause	a	poor	probability	of	BC	for	included	CM	cases	was	expected.	
This	 study	 resulted	 in	 much	 lower	 BC	 rates	 for	 CM	 cases	 treated	
with	 antibiotics	 (AB	 group	37.2%;	ABMV	group	39.1%)	 in	 compari-
son	with	other	studies,	which	showed	a	BC	rate	of	approximately	70%	
(Schukken	et	al.,	2013;	Swinkels	et	al.,	2014).	The	high	differences	in	
BC	 rates	 support	 the	selection	criteria	used	 in	 this	 study	 to	choose	
cows	 suffering	 from	CM	with	 a	 low	 likelihood	of	BC.	Nevertheless,	
a	 tendency	 for	 the	 efficacy	 of	 antibiotic	 treatment	 against	 masti-
tis	pathogens	was	shown.	The	probability	of	BC	in	the	nonantibiotic	
treatment	 group	 (MV)	 was	 27.5%	 and	 therefore	 numerically	 lower	
than	 the	BC	 rate	 in	 the	 reference	 treatment	 group.	However,	 there	
were	no	significant	differences	between	MV	and	AB	group	(p = .151).	
Noninferiority	was	inconclusive	because	CI	spans	both	−∆	and	0.	This	
may	be	due	to	the	fact	that	the	real	difference	not	being	higher	than	
the	observed	15%.	Between	the	ABMV	and	AB	group	were	small	nu-
merical	differences	without	significant	associations	and	noninferiority	
was	inconclusive.
The	evaluations	of	noninferiority	 resulted	mostly	 in	 inconclusive	
findings.	A	larger	sample	size	in	all	treatment	groups	is	required	to	con-
firm	the	detected	results	of	the	study	and	to	make	a	clear	statement	
on	noninferiority.
The	 main	 interests	 of	 the	 farmers	 are	 disappearance	 of	 clinical	
signs,	a	low	recurrence	rate	and	a	short	time	of	discarding	milk	(Ruegg,	
2010).	With	respect	to	the	primary	outcomes,	Masti	Veyxym®	seems	
to	show	similar	results	in	comparison	with	the	reference	group	treated	
with	 antibiotics.	 Furthermore,	 advantageous	 properties	 of	 Masti	
Veyxym®	 are	 the	 short	withdrawal	 period	 for	 milk	 of	 1	day,	which	
decreases	time	of	discarding	milk,	and	that	it	contains	no	antibiotics,	
resulting	in	a	reduced	risk	of	residues	and	improved	safety.
Another	interesting	outcome	variable	for	farmers	assessing	a	suc-
cessful	treatment	 is	the	course	of	the	CSCC,	because	 it	 is	used	as	a	
measure	of	milk	quality.	In	this	study,	cows	with	persistent	high	CSCC	
were	chosen	and	a	low	probability	of	BC	was	expected	and	confirmed.	
F IGURE  1 Main	results	of	this	noninferiority	trial.	Black	point	
presents	point	estimate	of	difference	in	outcome	variables	between	
the	test	treatments	(MV;	ABMV)	and	the	reference	treatment	(AB)	
with	the	associated	95%	CI	indicated	by	the	arrowheads.	Dark	
field	represents	area	of	noninferiority.	Clinical	cure	=	difference	in	
CC	between	test	treatments	MV	(A)	and	ABMV	(B)	in	comparison	
with	AB	group,	the	CI	spans	both	0	and	noninferiority	margin	(−∆),	
noninferiority	is	inconclusive	and	there	are	no	significant	differences	
between	the	two	treatments.	No	recurrence	60	days	=	difference	in	
no	R60	between	test	treatments	MV	(C)	and	ABMV	(D)	in	comparison	
with	AB	group.	C:	The	CI	spans	both	0	and	−∆,	noninferiority	is	
inconclusive	and	there	are	no	significant	differences	between	the	
two	treatments.	D:	The	CI	spans	0	but	not	−∆,	noninferiority	is	
proven	and	there	are	no	significant	differences	between	the	two	
treatments.	Bacteriological	cure	(BC)	=	difference	in	BC	between	test	
treatments	MV	(E)	and	ABMV	(F)	in	comparison	with	AB	group,	the	CI	
spans	both	0	and	−∆,	noninferiority	is	inconclusive	and	there	are	no	
significant	differences	between	the	two	treatments
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Variable
Coefficient
OR 95% CI p- valueaX SE
Intercept 1.759 1.323 5.805 0.405–83.149 .190
Treatment
MV −0.475 0.804 0.622 0.125–3.086 .556
ABMV 1.306 0.753 3.693 0.822–16.590 .087
AB	(reference) 0
Lactation	number	of	the	cow	at	the	day	of	clinical	mastitis	occurrence
1 1.843 0.809 6.315 1.260–31.665 .026
2 2.137 0.791 8.476 1.752–41.006 .009
>2	(reference) 0
Days	in	milk	at	the	day	of	clinical	mastitis	occurrence
0–100 −2.815 1.050 0.060 0.007–0.486 .009
101–200 −1.939 0.941 0.144 0.022–0.940 .043
>200	(reference) 0
Pathogen	cultured	from	the	pretreatment	milk	sample
Enterobacteriaceae −1.002 1.744 0.367 0.011–11.887 .567
Streptococci 0.628 0.980 1.873 0.265–13.221 .524
Staphylococci −2.028 1.008 0.132 0.018–0.982 .048
Other	pathogens −0.510 0.884 0.601 0.103–3.501 .566
Contaminated	
sample
−1.888 1.767 0.151 0.004–5.128 .289
No	growth	
(reference)
0
aSignificance	set	at	p < .05.	Bold	value	indicates	significant	value.
TABLE  4 Final	mixed	logistic	regression	
model	results	for	the	primary	outcome	
variable	no	recurrence	60	days.	Three	
different	treatment	regimens	were	
investigated:	MV,	solely	Masti	Veyxym®,	
comprising	three	treatments	at	an	interval	
of	12	hr;	ABMV,	antibiotic	treatment	as	
usual	on	the	farm	according	to	label	of	the	
respective	product	combined	with	Masti	
Veyxym®,	comprising	three	treatments	at	
an	interval	of	12	hr;	AB,	antibiotic	
treatment	as	usual	on	the	farm	according	
to	label	of	the	respective	product
Variable
Coefficient
OR 95% CI p- valueaX SE
Intercept 0.563 0.544 1.756 0.598–5.153 .302
Treatment
MV 0.808 0.559 2.243 0.741–6.786 .151
ABMV 0.303 0.531 1.353 0.473–3.871 .570
AB	(reference) 0
Lactation	number	of	the	cow	at	the	day	of	clinical	mastitis	occurrence
1 −0.284 0.539 0.753 0.259–2.189 .599
2 0.274 0.464 1.315 0.525–3.297 .556
>2	(reference) 0
Days	in	milk	at	the	day	of	clinical	mastitis	occurrence
0–100 0.186 0.604 1.204 0.364–3.985 .759
101–200 −1.577 0.488 0.207 0.079–0.543 .002
>200	(reference) 0
Pathogen	cultured	from	the	pretreatment	milk	sample
Enterobacteriaceae 0.103 0.887 1.109 0.191–6.424 0.908
Streptococci 0.766 0.510 2.151 0.784–5.905 0.136
Staphylococci 0.747 0.528 2.111 0.742–6.008 0.160
Other	pathogens	
(reference)
0
aSignificance	set	at	p < .05.	Bold	value	indicates	significant	value.
TABLE  5 Final	mixed	logistic	regression	
model	results	for	the	secondary	outcome	
variable	bacteriological	cure.	Three	
different	treatment	regimens	were	
investigated:	MV,	solely	Masti	Veyxym®,	
comprising	three	treatments	at	an	interval	
of	12	hr;	ABMV,	antibiotic	treatment	as	
usual	on	the	farm	according	to	label	of	the	
respective	product	combined	with	Masti	
Veyxym®,	comprising	three	treatments	at	
an	interval	of	12	hr;	AB,	antibiotic	
treatment	as	usual	on	the	farm	according	
to	label	of	the	respective	product
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The	 antibiotic	 treatment	 can	 only	 affect	 the	 BC	 and	 at	 best	 elimi-
nate	the	causing	pathogen.	Only	in	the	successful	case	of	BC	can	be	
achieved	a	CC	and	a	noticeable	reduction	in	CSCC	(Degen	et	al.,	2015).	
Overall,	only	9.88%	of	the	examined	CM	cases	reached	a	QSCC	cure	
and	no	significant	differences	between	the	treatment	groups	were	ob-
served.	This	percentage	is	 lower	than	results	of	a	recently	published	
study	of	Swinkels	et	al.	(2014).	They	showed	an	overall	QSCC	cure	of	
22%,	which	suggests	 that	a	cow	with	 the	used	selection	criteria	 for	
this	study	has	got	a	very	 low	probability	to	recover	a	normal	SCC	in	
the	affected	udder	quarter.	The	low	QSCC	cure	rate	by	a	CC	rate	of	
approximately	60%	indicates	that	the	observed	CM	cases	may	convert	
into	a	subclinical	stage	with	still	elevated	QSCC.
Our	intention	was	to	reflect	the	situation	in	daily	practice	on	dairy	
farms.	That	 implies	 no	 information	 about	 the	 causative	 pathogen	 at	
the	time	of	CM	treatment.	Therefore,	and	because	power	calculations	
were	 made	 on	 overall	 therapy	 level,	 evaluations	 of	 treatment	 effi-
cacy	at	a	pathogen	level	gave	no	reliable	results	due	to	lack	of	power.	
Moreover,	farmers	were	allowed	to	use	their	normal	mastitis	treatment	
procedure.	That	resulted	in	a	wide	range	of	used	antibiotics	with	dif-
ferent	durations	of	treatment	and	withholding	periods.	However,	there	
were	no	indications	of	the	various	therapies	affecting	the	study	results.
No	completely	untreated	control	group	was	included	in	our	investiga-
tion.	There	are	some	reasons	for	this.	Clinical	mastitis	is	a	disease	which	
is	accompanied	with	pain,	suffering	and	harm	for	 the	cow.	Therefore,	
solely	for	reasons	of	the	animal	welfare	a	treatment	is	indicated.	The	par-
ticipated	farms	were	all	geared	to	economic	principles	and	in	the	normal	
production	cycle.	It	was	not	possible	to	leave	cows	with	CM	untreated	
without	any	evidence-	based	information.	Furthermore,	they	mostly	did	
not	differentiate	between	a	first	CM	case	and	a	chronic	mastitis,	all	CM	
cases	were	treated	with	antibiotics.	Finally,	prior	to	the	study	we	were	
unaware	if	the	chosen	selection	criteria	for	cows	are	really	suitable	to	
identify	cows	with	CM	expecting	a	poor	probability	of	BC.
5  | CONCLUSIONS
A	randomized,	multiherd,	noninferiority	study	was	conducted	evalu-
ating	the	efficacy	of	the	test	 treatments	Masti	Veyxym®	 (MV)	and	
combined	Masti	 Veyxym®	 with	 antibiotics	 (ABMV)	 in	 comparison	
with	 antibiotic	 treatment	 (AB;	 reference)	 of	mild-	to-	moderate	CM	
in	cows	with	longer	lasting	udder	diseases.	The	two	test	treatments	
showed	no	significant	differences	 to	 the	 reference	 treatment	with	
respect	 to	 the	 outcome	 variables	 such	 as	 clinical	 cure,	 no	CM	 re-
currence	 within	 60	days	 after	 the	 end	 of	 therapy,	 bacteriological	
cure	 and	quarter	 somatic	 cell	 count	 cure.	 The	 solely	 nonantibiotic	
therapy	 showed	 a	 numerically	 lower	 probability	 of	 bacteriological	
cure	without	significant	differences	to	the	reference	treatment.	The	
combined	treatment	group	(ABMV)	resulted	in	a	numerically	higher	
nonrecurrence	rate	than	the	two	other	therapy	groups	(MV	and	AB)	
and	noninferiority	compared	to	the	reference	treatment	was	proven.	
The	study	findings	indicate	that	using	solely	Masti	Veyxym®	in	treat-
ment	 of	 mild-	to-	moderate	 CM	 in	 cows	 with	 longer	 lasting	 udder	
diseases	may	 constitute	 an	 alternative	 therapy	 to	 reduce	 antibiot-
ics.	However,	 to	 give	 a	 reliable	 noninferiority	 evaluation,	 a	 higher	
sample	size	is	needed.	The	selection	criteria	of	cows	have	to	be	re-
spected,	 and	 it	 is	 recommended	 to	 remove	 such	 animals	 from	 the	
herd	if	possible.
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